首页> 外文期刊>The Journal of Immunology: Official Journal of the American Association of Immunologists >Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients
【24h】

Expansion of SARS-CoV-2-Specific Antibody-Secreting Cells and Generation of Neutralizing Antibodies in Hospitalized COVID-19 Patients

机译:住院 COVID-19 患者中 SARS-CoV-2 特异性抗体分泌细胞的扩增和中和抗体的产生

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Coronavirus disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), emerged in late 2019 and has since become a global pandemic. Pathogen-specific Abs are typically a major predictor of protective immunity, yet human B cell and Ab responses during COVID-19 are not fully understood. In this study, we analyzed Ab-secreting cell and Ab responses in 20 hospitalized COVID-19 patients. The patients exhibited typical symptoms of COVID-19 and presented with reduced lymphocyte numbers and increased T cell and B cell activation. Importantly, we detected an expansion of SARS-CoV-2 nucleocapsid protein-specific Ab-secreting cells in all 20 COVID-19 patients using a multicolor FluoroSpot Assay. Out of the 20 patients, 16 had developed SARS-CoV-2-neutralizing Abs by the time of inclusion in the study. SARS-CoV-2-specific IgA, IgG, and IgM Ab levels positively correlated with SARS-CoV-2-neutralizing Ab titers, suggesting that SARS-CoV-2-specific Ab levels may reflect the titers of neutralizing Abs in COVID-19 patients during the acute phase of infection. Last, we showed that IL-6 and C-reactive protein serum concentrations were higher in patients who were hospitalized for longer, supporting the recent observations that IL-6 and C-reactive protein could be used as markers for COVID-19 severity. Altogether, this study constitutes a detailed description of clinical and immunological parameters in 20 COVID-19 patients, with a focus on B cell and Ab responses, and describes tools to study immune responses to SARS-CoV-2 infection and vaccination.
机译:2019 年冠状病毒病 (COVID-19) 由严重急性呼吸系统综合症冠状病毒 2 (SARS-CoV-2) 引起,于 2019 年底出现,此后已成为全球大流行。病原体特异性抗体通常是保护性免疫的主要预测指标,但 COVID-19 期间的人 B 细胞和抗体反应尚不完全清楚。在这项研究中,我们分析了 20 名住院 COVID-19 患者的 Ab 分泌细胞和 Ab 反应。患者表现出 COVID-19 的典型症状,并表现为淋巴细胞数量减少,T 细胞和 B 细胞活化增加。重要的是,我们使用多色荧光斑点测定在所有 20 名 COVID-19 患者中检测到 SARS-CoV-2 核衣壳蛋白特异性 Ab 分泌细胞的扩增。在 20 名患者中,有 16 名在纳入研究时已经发展为 SARS-CoV-2 中和抗体。SARS-CoV-2 特异性 IgA、IgG 和 IgM 抗体水平与 SARS-CoV-2 中和抗体滴度呈正相关,提示 SARS-CoV-2 特异性抗体水平可能反映了 COVID-19 患者在感染急性期中和抗体滴度。最后,我们发现住院时间较长的患者血清 IL-6 和 C 反应蛋白浓度更高,这支持了最近的观察结果,即 IL-6 和 C 反应蛋白可用作 COVID-19 严重程度的标志物。总之,本研究详细描述了 20 名 COVID-19 患者的临床和免疫学参数,重点是 B 细胞和抗体反应,并描述了研究对 SARS-CoV-2 感染和疫苗接种的免疫反应的工具。

著录项

获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号